Clinical benefit and prices of cancer drugs in the US and Europe

被引：0
|
作者：
Vokinger, K. N. [1 ]
Hwang, T. [2 ]
Tibau, A. [3 ]
Rosemann, T. J. [4 ]
Kesselheim, A. S. [5 ]
机构：
[1] Univ Hosp Zurich, Acad Chair Hlth Policy, Inst Primary Care, Fac Law, Zurich, Switzerland
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[4] Univ Zurich, Univ Zurich Hosp, Inst Primary Care, Zurich, Switzerland
[5] Harvard Med Sch, Program Regulat Therapeut & Law, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1631PD_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis
    Vokinger, Kerstin N.
    Hwang, Thomas J.
    Grischott, Thomas
    Reichert, Sophie
    Tibau, Ariadna
    Rosemann, Thomas
    Kesselheim, Aaron S.
    LANCET ONCOLOGY, 2020, 21 (05): : 664 - 670
  • [2] Prices and price developments of cancer drugs in the US and Europe
    Vokinger, K. N.
    Daniore, P.
    Hwang, T.
    Kesselheim, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1197 - S1198
  • [3] Pivotal trial endpoints and prices of cancer drugs in the US and Europe.
    Vokinger, Kerstin Noelle
    Daniore, Paola
    Hwang, Thomas J.
    Lee, ChangWon C.
    Kesselheim, Aaron S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
    Michaeli, Daniel Tobias
    Michaeli, Thomas
    PHARMACOECONOMICS, 2024, 42 (01) : 117 - 131
  • [5] Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
    Daniel Tobias Michaeli
    Thomas Michaeli
    PharmacoEconomics, 2024, 42 : 117 - 131
  • [6] Clinical benefitand prices of cancer drugs in the United States and Europe.
    Vokinger, Kerstin Noelle
    Hwang, Thomas J.
    Martorell, Ariadna Tibau
    Rosemann, Thomas J.
    Kesselheim, Aaron S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Tibau, Ariadna
    Molto, Consolacion
    Ocana, Alberto
    Templeton, Arnoud J.
    Del Carpio, Luis P.
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 486 - 492
  • [8] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Cherny, Nathan I.
    Dafni, Urani
    Bogaerts, Jan
    Latino, Nicola J.
    Pentheroudakis, George
    Douillard, Jean-Yves
    Tabernero, Josep
    Zielinski, Christoph
    Piccart, Martine J.
    de Vries, Elisabeth G. E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10):
  • [9] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    CANCER, 2020, 126 (19) : 4390 - 4399
  • [10] Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe
    Hwang, T.
    Vokinger, K.
    Tibau, A.
    Gyawali, B.
    Naci, H.
    Franklin, J. M.
    Beall, R.
    Kesselheim, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 752 - 752
12345